



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF
Mikayama et al.

Confirmation No.: 1366

Appln. No.: 10/693,629

Group Art Unit: 1644

Filed: October 23, 2003

Examiner: To be assigned

Title: ANTI-CD40 MONOCLONAL ANTIBODY

TRANSMITTAL LETTER

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence along with any paper referred to as being attached is being Mailed to Addressee by service of the United States Postal Service addressed to Commissioner for Patents, P.O. Box, 1450, Alexandria, VA 22313-1450

Date: January 3, 2005 By:


Sachiko Y. Snedden

Sii:

Transmitted herewith for filing are the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copy of Supplementary Partial European Search Report mailed November 18, 2004;
4. Cited References (4); and
5. Return Postcard.

No fee is incurred for filing this Statement. However, the Commissioner is hereby authorized to charge any fee that may be due in connection with this and the attached papers, or with this application during its entire pendency, or to credit any overpayment to Deposit Account 50-2212, Order No. 021286-0306473. A duplicate of this Transmittal is enclosed.


Respectfully submitted,

Pillsbury Winthrop LLP

Date: January 3, 2005

11682 El Camino Real, Suite 200
San Diego, CA 92130-2092
(619) 234-5000

By:


Robert M. Bedgood, Ph.D.
Reg. No. 43,488
Tel. No. (858) 509-4065
Fax No. (858) 509-4010

Docket Number: 021286-0306473

PATENT APPLICATION

Client Reference: PH-1569US-CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

TOSHIFUMI MIKAYAMA, et al.

Group Art Unit: 1644

Application No.: 10/693,629

Examiner: To be assigned

Filed: October 23, 2003

Confirmation No.: 1366

For: ANTI-CD40 MONOCLONAL ANTIBODY

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Applicants respectfully request the Examiner return an initialed copy of the enclosed Form PTO-1449 to Applicants with the next Office communication to indicate that the reference(s) has been considered, per MPEP § 609.

CERTIFICATION UNDER 37 C.F.R. §§ 1.8 and/or 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*; Express Mail certification is *optional*.)

I hereby certify that, on the date shown below, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: January 3, 2005


Signature

SACHIKO Y. SNEDDEN


(type or print name of person certifying)

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of the first Office Action on the merits in the present application. No certification or fee is required.

The reference(s) was/were cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information.

Respectfully Submitted,



Robert M. Bedgood
Registration Number 43488
Customer Number: 27500

Date: January 3, 2005
PILLSBURY WINTHROP LLP
Telephone: (619) 234-5000
Facsimile: (858) 509-4010
11682 El Camino Real
Suite 200
San Diego, CA 92130-2092

[illegible]

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty.
Dkt. No.

C-M#

Client Ref.

021286-0306473

PH-1569US-CIP

Applicant: Mikayama et al.

Appln. No.: 10/693,629

Filing Date: October 23, 2003

Examiner: To be assigned Art Unit: 1644

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: January 3, 2005

Page

2

of

2

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's

Initials*

BR

Yamada et al., "Generation of Mature Dendritic Cells from a CD14⁺ Cell Line (XS52) by IL-4, TNF- α , IL-1 β , and Agonistic Anti-CD40 Monoclonal Antibody", *J. Immunol.*, 1999; 163(10): 5331-5337, XP002302209

CR

van Kooten et al., "Functions of CD40 on B cells, dendritic cells and other cells", *Curr. Opin. Immunol.*, 1997; 9(3): 330-337, XP004313522

DR

Stout et al., "The many roles of CD40 in cell-mediated inflammatory responses", *Immunol. Today*, 1996; 17(10): 487-492, XP004034711

English

Abstract

Translation

Readily
Available

Enclosed

No

Enclosed

No

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.